Cardiff Oncology
CRDF
22 hedge funds and large institutions have $20.5M invested in Cardiff Oncology in 2014 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 5 closing their positions.
1% more capital invested
Capital invested by funds: $20.3M → $20.5M (+$229K)
15% less funds holding
Funds holding: 26 → 22 (-4)
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Top Buyers
Top Sellers
| 1 |
VKH
Virtu KCG Holdings
New York
|
-$125K |
| 2 |
AGM
Alpine Global Management
New York
|
-$105K |
| 3 |
Morgan Stanley
New York
|
-$101K |
| 4 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$73K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$32K |
CRDF Hedge Fund Activity: Q1 2014 in Review
22 of the 3,462 institutional investors tracked by Wall St. Rank reported a position in Cardiff Oncology (CRDF) for Q1 2014, worth a combined $20.5M — up 1.1% from $20.3M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of CRDF and 1 opened new positions — a net loss of 4 holders — while 6 trimmed existing stakes and 4 added.
The largest buyer was Cambridge Investment Research Advisors, adding an estimated $327K. The largest seller was Virtu KCG Holdings, exiting entirely with an estimated $125K sold.
- 22 institutional investors held Cardiff Oncology (CRDF) as of Q1 2014, down from 26 in Q4 2013.
- Funds reported $20.5M of Cardiff Oncology stock for Q1 2014, up 1.1% quarter-over-quarter.
- 1 fund opened new Cardiff Oncology positions in Q1 2014 and 5 closed out, a net change of -4 holders.
- The largest Cardiff Oncology buyer in Q1 2014 was Cambridge Investment Research Advisors, an estimated $327K added.
- The largest Cardiff Oncology seller in Q1 2014 was Virtu KCG Holdings, an estimated $125K sold.
Based on aggregated 13F filings for Q1 2014.